

# Nonalcoholicsteatohepatitis (NASH) Treatment Pipeline Review 2017

---

*Nonalcoholicsteatohepatitis (NASH) Market 2017 Global Trends, Pipeline Review, Market Share, Industry Size, Growth, Opportunities, and Forecast to 2022*

PUNE, INDIA, February 22, 2017 /EINPresswire.com/ -- Description:

Non-alcoholic steatohepatitis (NASH) Pipeline Analysis" gives comprehensive insights on the various drugs being developed for the treatment of NASH. The report covers all the drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, antibodies, stem cell therapies, recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations and supplemental drugs. The report also covers some of the hot targets in research for NASH treatments and NASH related biomarkers.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/988074-nonalcoholicsteatohepatitis-nash-pipeline-analysis-one>

This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Non-alcoholic steatohepatitis (NASH) drugs market. The report also provide strategic insights on some of the molecules that are yet to be launched in the next few years. Some of the key sections covered in the report are given below:

## Epidemiology

In this section, epidemiology of NASH is reviewed to understand potential significance and impact of the disease.

Global & US prevalence rates  
Hot Targets, Mechanisms & Therapies

In this section, various NASH associated targets, mechanism and upcoming therapies are discussed. Also, covers novel targets in early research for NASH along with disease progression biomarkers associated with NASH (Inflammatory, apoptosis, fibrosis)

## Market analysis

In market analysis section, global NASH drugs market is indicated along with the estimated Peak sales (\$) of leading clinical stage drugs forecasted from 2019-2025.

## Forecasting model for NASH market

NASH market dynamics

NASH Market and estimated Peak sales of 8 clinical candidates (OCA-Intercept, Aramchol-Galmed, GR-MD-02-Gilead, Cenicriviroc-Tobira, Simtuzumab-Gilead, Remo Biphasic-Avolynt, IVA 337-Inventiva Pharma, GFT505-Genfit)

NASH related deals analysis with financials (upfront, milestones and royalties)

## Funding scenario in NASH market

### Pipeline Analysis

Pipeline analysis was carried to get deeper insights on various treatment modalities in discovery, preclinical & development section, pipelines from major companies were identified and Potential targets were reported along with Mechanism of action, Current development status & nature of molecule. Pipeline analysis by developmental stage (Discovery to Clinical development)

### Pipeline analysis by modalities

Monoclonal Antibodies pipeline analysis

RNA-therapeutics pipeline analysis

Recombinant protein pipeline analysis

Pipeline analysis by leading players & Target analysis

Drug analysis based on mechanism (Anti-Inflammatory, Anti-fibrotic & Metabolic)

### Key Players Analysis

The key player's analysis section provides an in-depth understanding of various companies working on Nonalcoholic steatohepatitis (NASH) and their Pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.

Global key players overview

Global key players Pipeline data (Discovery, Pre-clinical & Clinical development)

Global key players deals (Collaborations, Licensing, Service agreements, grants, funds)

Complete Report @ <https://www.wiseguyreports.com/reports/988074-nonalcoholicsteatohepatitis-nash-pipeline-analysis-one>

### Table of Contents

#### REPORT DESCRIPTION

##### INTRODUCTION

- Causes & Symptoms
- Diagnosis
- Unmet needs
- Current therapies

#### HOT TARGETS, MECHANISMS & THERAPIES

- Novel Disease mechanisms & therapies
- Leading & hot targets of NASH
- Novel targets of NASH
- NASH biomarkers
- Genes involved in NASH

#### MARKET DATA

- Forecasting model
- Market dynamics
- Market sizing
- NASH Deals
- Funding Scenario

#### PIPELINE ANALYSIS

- Development stage
- Leading players
- Therapeutic segmentation
- Target analysis
- Clinical update on Phase 3 molecules
- Innovative approaches

Small molecules

- Pipeline
- Competitive landscape

Large molecules

- Competitive landscape

RNA-BASED THERAPY

- Pipeline
- Competitive landscape

RECOMBINANT PROTEINS

- Pipeline
- Competitive landscape

ANTIBODIES

- Pipeline
- Competitive landscape

LARGE MOLECULES (UNSPECIFIED)

- Pipeline

OTHER MOLECULES

- Pipeline

NASH DRUG ANALYSIS BASED ON MECHANISM

MAJOR PLAYERS

- Company Profiles
- Overview, Pipeline & Deals

REFERENCE

Get It Now @ [https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=988074](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=988074)

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.